Press release
Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Prurigo Nodularis Pipeline. Dive into DelveInsight's comprehensive report today! @ Prurigo Nodularis Pipeline Outlook [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Prurigo Nodularis Marketed and Pipeline Drugs Report
* In May 2025, Incyte Corporation announced a study to evaluate the effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
* In May 2025, Amgen conducted a phase 3 study to assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies.
* DelveInsight's Prurigo Nodularis Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Prurigo Nodularis treatment.
* The leading Prurigo Nodularis Companies such as Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho, and others.
* Promising Prurigo Nodularis Pipeline Therapies such as Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
Stay ahead with the most recent pipeline outlook for Prurigo Nodularis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prurigo Nodularis Treatment Drugs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prurigo Nodularis Emerging Drugs Profile
* Nemolizumab: Chugai/Galderma
Nemolizumab was discovered by Chugai, and uses Chugai's proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage of development.
* Nalbuphine ER: Trevi Therapeutics
Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.
* Vixarelimab: Kiniksa Pharmaceuticals
Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMR). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.
The Prurigo Nodularis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Prurigo Nodularis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis Treatment.
* Prurigo Nodularis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Prurigo Nodularis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement,s and financing details for future advancement of the Prurigo Nodularis market
Explore groundbreaking therapies and clinical trials in the Prurigo Nodularis Pipeline. Access DelveInsight's detailed report now! @ New Prurigo Nodularis Drugs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prurigo Nodularis Companies
Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Prurigo Nodularis Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Unveil the future of Prurigo Nodularis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Prurigo Nodularis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Prurigo Nodularis Pipeline Report
* Coverage- Global
* Prurigo Nodularis Companies- Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
* Promising Prurigo Nodularis Pipeline Therapies- Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
* Prurigo Nodularis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Prurigo Nodularis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Prurigo Nodularis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Prurigo Nodularis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Prurigo Nodularis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Prurigo Nodularis - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Prurigo Nodularis Collaboration Deals
* Late Stage Products (Phase III)
* Nemolizumab: Chugai/Galderma
* Nalbuphine ER: Trevi Therapeutics
* Mid Stage Products (Phase II)
* Vixarelimab: Kiniksa Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Prurigo Nodularis Key Companies
* Prurigo Nodularis Key Products
* Prurigo Nodularis- Unmet Needs
* Prurigo Nodularis- Market Drivers and Barriers
* Prurigo Nodularis- Future Perspectives and Conclusion
* Prurigo Nodularis Analyst Views
* Prurigo Nodularis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prurigo-nodularis-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4024328 • Views: …
More Releases from ABNewswire
InsureAustinTX.com Launches to Provide Smart Insurance Solutions for Austin Fami …
InsureAustinTX.com, the newest online platform from Baxter Insurance Agency, Inc., is set to launch on January 13, 2026, offering Austin residents a streamlined way to find and compare local insurance options for auto and home coverage.
AUSTIN, TX - Jan 13, 2026 - Baxter Insurance Agency, Inc., a trusted name in Texas insurance for over four decades, is proud to announce the launch of its latest website, InsureAustinTX.com. This new platform…
Best ADU Builders in St. Petersburg, FL (2026 Review): Zoning, Cost & Contractor …
A 2026 market review examines how homeowners in St. Petersburg, Florida are evaluating ADU builders under stricter zoning and permitting enforcement. The report compares contractor types, highlights common project failures, and explains why design-build firms are increasingly preferred for compliant accessory dwelling unit construction.
ST. PETERSBURG, FL - January 13, 2026 - As demand for accessory dwelling units (ADUs) continues to rise across St. Petersburg and Pinellas County, homeowners are facing…
How to Draw a Corgi: A Creative Guide to Relaxation and Mindfulness
New Book Confessions of a Corgi Doodler Turns Simple Sketches Into a Philosophy for Creative Living
MARIETTA, GA - The new book Confessions of a Corgi Doodler [https://www.amazon.com/Confessions-Corgi-Doodler-Nancy-Kondos/dp/1966972717/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.eK5vqZKYyVTf8-wHEYO8Bw.pJTT3UgaTroxKgcIHzvQiAWCz1FNpLKHBjvk9qWGepE&qid=1765308929&sr=1-1] begins with a single instruction: lose your predictions. Let the pen dance. What follows is not just a guide to drawing the charming, short legged dog, but a series of illustrated revelations on creativity itself. Published by Author's Tranquility Press, this volume by…
Amidst the Silence of Loss A New Voice Emerges
The new book "Live Again: A Widow's Guide to Healing and Recovery" by Alene Maag offers a compassionate and practical resource for the journey through widowhood.
MARIETTA, GA - In the quiet aftermath of a spouse's death, a crushing duality descends: an ocean of private grief and a mountain of public, practical demands. This isolating space now has a thoughtful new companion. "Live Again: A Widow's Guide to Healing and Recovery…
More Releases for Prurigo
Prurigo Nodularis Market to Witness Promising Upswing by 2034, DelveInsight Fore …
DelveInsight's "Prurigo Nodularis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Prurigo Nodularis, historical and forecasted epidemiology as well as the Prurigo Nodularis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Prurigo Nodularis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prurigo Nodularis Market Forecast
https://www.delveinsight.com/sample-request/prurigo-nodularis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Prurigo Nodularis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Prurigo nodularis (PN) is a rare, chronic inflammatory skin disease characterized by intensely itchy nodules that severely impair quality of life. The exact cause remains unclear, but PN is linked to immune dysregulation, chronic pruritus pathways, and systemic diseases such as atopic dermatitis, diabetes, and liver disorders. For decades, management relied on corticosteroids, antihistamines, and immunosuppressants, with limited efficacy and safety concerns in long-term use.
The landscape has changed dramatically with…
Prurigo Nodularis Treatment Market Opportunities & Challenges, Novel Therapies T …
The Global Prurigo Nodularis Treatment Market reached USD 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2031. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2024-2031.
Prurigo Nodularis Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to…
Prurigo Nodularis Pipeline: Emerging Therapies Set to Reshape the Prurigo Nodula …
The treatment landscape of Prurigo Nodularis (PN), a chronic, intensely pruritic skin disorder, is undergoing a dynamic transformation, fueled by a growing pipeline of novel therapeutics from leading pharma and biotech companies. Notable players such as Menlo Therapeutics, Galderma R&D, and Kiniksa Pharmaceuticals are driving innovation with therapies targeting underlying immune dysregulation, including IL-31 and JAK/STAT pathways, central to PN pathogenesis. These emerging drugs aim to address the high unmet…
Prurigo Nodularis Treatment Market Current Status and Future Prospects till 2031
Prurigo Nodularis (PN) is a chronic dermatologic condition marked by intense itching and the development of nodules on the skin. The Prurigo Nodularis Treatment Market focuses on therapeutic interventions to alleviate symptoms and provide relief to patients suffering from this condition. Treatments include topical corticosteroids, immunosuppressants, and biologic therapies. The current market value of Prurigo Nodularis treatment is driven by the increasing awareness of PN and advancements in treatment options.…
Prurigo Nodularis Treatment Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Prurigo Nodularis Treatment Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.
Market Overview for Prurigo Nodularis Treatment Market
Prurigo Nodularis Treatment Market OverviewPrurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules or papules that can significantly impair quality of…
